Meet Opprtna Therapeutics, the future of aptamer-based drug discovery. Our mission is the pursuit of novel diagnostics and treatments for Cancer and CNS disorders using cutting-edge XNA technology.
Meet the leaders for Opprtna who want to make a difference for the patients
Ganesh Iyer, PhD
CEO & Founder
Cindy Benod, PhD, MBA
COO
Research Team
Scientists
What are aptamers?
Aptamers are synthetic, high-affinity DNA or RNA molecules that can selectively bind to specific targets, including proteins and small molecules. They hold great promise for both diagnostics and therapeutics.
Why XNA technology?
XNA stands for Xeno Nucleic Acid, a synthetic alternative to DNA and RNA. XNA-based aptamers have increased stability, affinity, and specificity, enhancing their potential for therapeutic applications.
How do you ensure quality?
Our drug discovery process is driven by state-of-the-art technology and rigorous validation processes, ensuring the delivery of the finest and most effective aptamers to clinicians and patients alike.
Subscribe Now